STADA
German pharmaceutical company focused on consumer healthcare, generic medicines and specialty pharmaceuticals.
Last updated October 6, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
STADA Arzneimittel AG is a German pharmaceutical company headquartered in Bad Vilbel. Its business is organized around three principal areas: consumer healthcare, generic medicines and specialty pharmaceuticals. The company supplies prescription and non-prescription products through pharmacies, wholesalers, hospitals and other healthcare channels, with operations and sales extending well beyond Germany. STADA traces its origins to 1895, when it was established in Dresden as a cooperative organization of pharmacists. The name was derived from “Standardarzneimittel Deutscher Apotheker,” referring to standardized medicines for German pharmacists. After the Second World War, the organization moved first to Essen and Tübingen before settling in Bad Vilbel in 1956. It began trading publicly in 1970, initially using registered shares whose transfer was restricted to pharmacists. In 1975, STADA entered the generic-drug market, which later became one of the central pillars of its business model. From the late 1990s through the 2010s, STADA expanded internationally through subsidiaries, acquisitions and partnerships. The company strengthened its generic-drug presence in Spain, Italy, the United Kingdom, Portugal, Russia and other markets, while also adding consumer-health and specialty products. Important transactions included the acquisition of American generic supplier MOVA Laboratories, Spanish company Bayvit, a controlling interest in Russian pharmaceutical group Nizhpharm, and UK over-the-counter manufacturer Thornton & Ross. The group also developed positions in nutritional supplements and dermatological products. STADA’s branded consumer-health portfolio has included products such as Grippostad-C cold medicine, Silomat cough remedies, Ladival sun protection products, lactulose and paracetamol or acetaminophen products sold under STADA-related brands. Its generic business supplies medicines whose active ingredients are available across a range of therapeutic areas, while its specialty-pharma activities address selected products and indications requiring more focused commercial or medical support. The company became the subject of an intense takeover process in 2017. After several possible bidders showed interest, Bain Capital and Cinven ultimately agreed to acquire STADA through the Nidda Healthcare structure. Their first tender offer did not meet the required acceptance threshold, but a subsequent offer succeeded in August 2017. STADA subsequently operated as a privately held pharmaceutical group rather than as a broadly publicly traded German company. STADA has also participated in charitable and sponsorship initiatives, including support for dolphin aid e.V. and a Romanian children’s village in Timișoara. Its commercial positioning combines the scale and cost discipline of a generic-drug manufacturer with the consumer recognition of over-the-counter brands and the higher specialization of selected prescription products. In 2022, the company reported revenue of €3.79 billion.
History
STADA traces its origins to 1895 in Germany. The organization began within the German pharmacy sector and gradually developed into a pharmaceutical business serving the needs of pharmacists, healthcare professionals, and patients. Its early identity was associated with cooperation and the supply of medicines through the pharmacy channel. Over the course of the twentieth century, STADA expanded its pharmaceutical activities and established a broader commercial presence. As generic medicines became increasingly important to healthcare systems, the company developed a substantial position in the supply of off-patent medicines. Generic products enabled STADA to compete through manufacturing capability, regulatory expertise, portfolio breadth, and distribution rather than relying primarily on discovery of new molecular entities. The company later complemented generics with consumer healthcare and specialty pharmaceuticals. Consumer healthcare gave STADA access to self-care categories in which established brands, pharmacy relationships, and consumer recognition are important. Specialty pharmaceuticals added products requiring more specialized development, regulatory management, or commercial support. The resulting three-pillar structure—consumer healthcare, generics, and specialty pharma—became the central description of the group's business model. STADA also internationalized its operations. It built and acquired businesses in multiple markets, while retaining a strong base in Germany and Europe. Its international portfolio included products marketed under different local and global brand names, reflecting the fragmented nature of pharmaceutical regulation and healthcare distribution. This approach allowed the company to combine global scale with market-specific portfolios. For a significant period, STADA operated as a publicly traded German pharmaceutical company. The group became the subject of a takeover process in 2017, when Bain Capital and Cinven acquired the company. Following the transaction, STADA was delisted and continued as a privately owned pharmaceutical group. This marked a major change in ownership and capital-market status, but not an end to the operating business. In its current form, STADA presents itself as an international healthcare company focused on consumer healthcare, generics, and specialty pharmaceuticals. Its business serves both professional healthcare channels and consumers. The company is therefore distinct from a single consumer product brand: STADA is a corporate pharmaceutical group with a portfolio of prescription medicines, non-prescription products, and specialty therapies distributed across numerous markets.
Products and positioning
An international pharmaceutical and healthcare platform combining consumer healthcare, generics, and specialty pharmaceuticals, with a strong European operating base.
Prescription pharmaceuticals
Generic medicines
STADA's generic-medicines business supplies pharmaceutical products based on active ingredients whose exclusivity protections have expired. These medicines are intended to provide established therapies at more accessible prices and are distributed through pharmacies, healthcare providers, hospitals, and national reimbursement systems. The portfolio is market-specific because product approvals, naming, packaging, and reimbursement arrangements differ by country.
Over-the-counter and self-care products
Consumer healthcare
The consumer-healthcare portfolio includes non-prescription medicines and other self-care products intended for common health needs. Products may be sold through pharmacies, retailers, and other consumer channels, with brand recognition and local market execution playing an important role. STADA operates both internationally recognized and market-specific consumer-health brands within this business area.
Specialty medicines
Specialty pharmaceuticals
STADA's specialty-pharmaceuticals pillar comprises medicines with more differentiated clinical, regulatory, or commercial characteristics than conventional generics. These products can require specialized medical communication, focused distribution, or particular expertise in development and market access. The pillar broadens STADA's portfolio beyond high-volume off-patent medicines and everyday self-care products.
Brand decisions
2017
Acceptance of the Bain Capital and Cinven acquisitionM&ABackground
STADA was a publicly traded pharmaceutical group when it became the target of an acquisition by Bain Capital and Cinven.
Action taken
The acquisition was completed and STADA was subsequently taken private and delisted.
Aftermath
STADA continued operating as a privately owned pharmaceutical company, while its historical public-market ticker ceased to represent a current listing.
Recent events
Reported
STADA Romania announces investment in Turda factory[2]
STADA Romania announced a €48.3 million investment in a new production facility in Turda, Romania. The planned factory is intended to produce and package prescription and over-the-counter pharmaceuticals, primarily for European markets, and is planned for completion in October 2024.
Reported
STADA Corp announces partnership with No Kid Hungry[3]
STADA Corp announced a partnership with No Kid Hungry to help children across the United States access healthy meals. The announcement also identified Bio360 Probiotics and NUVIA as partners in the effort, which could provide up to 1.5 million meals.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/stada · Editorial policy · How profiles are compiled